AI assistant
GlaxoSmithKline PLC Director's Dealing 2024
5262_dirs_2024-03-13_66891b2e-3d18-4b4b-8773-f55892fdc0db.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 7499G
GSK PLC
13 March 2024
GSK plc (the ' Company ')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications & CEO Office
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of 9,000 Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.7189 | 9,000 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2024-03-11
f)
Place of the transaction
London Stock Exchange ( XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sally Jackson
b)
Position/status
SVP, Global Communications & CEO Office
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of 4,340 Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.7944 | 4,340 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2024-03-11
f)
Place of the transaction
London Stock Exchange ( XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dylan Jackson
b)
Position/status
PCA of Sally Jackson (SVP, Global Communications & CEO Office)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of 13,616 Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.6871 | 13,616 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2024-03-11
f)
Place of the transaction
London Stock Exchange ( XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dylan Jackson
b)
Position/status
PCA of Sally Jackson (SVP, Global Communications & CEO Office)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of 2,476 Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £16.7145 | 2,476 |
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
e)
Date of the transaction
2024-03-12
f)
Place of the transaction
London Stock Exchange ( XLON)
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, GSK Global Health | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of 60,000 Ordinary Shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.8004 | 60,000 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-03-12 | |||
| f) | Place of the transaction | London Stock Exchange ( XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 7 (partnership shares) | ||||
| £16.6610 | 7 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 14 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Julie Brown | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 8 (partnership shares) | ||||
| £16.6610 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 8 (partnership shares) | ||||
| £16.6610 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Sally Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 7 (partnership shares) | ||||
| £16.6610 | 7 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 14 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | David Redfern | |||
| b) | Position/status | President Corporate Development | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 8 (partnership shares) | ||||
| £16.6610 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 8 (partnership shares) | ||||
| £16.6610 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Philip Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 8 (partnership shares) | ||||
| £16.6610 | 8 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 16 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 7 (partnership shares) | ||||
| £16.6610 | 7 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 14 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Victoria Whyte | |||
| b) | Position/status | Company Secretary | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £16.6610 | 7 (partnership shares) | ||||
| £16.6610 | 7 (matching shares) | ||||
| d) | Aggregated information | ||||
| Aggregated volume Price | 14 Ordinary Shares £ 16.6610 |
||||
| e) | Date of the transaction | 2024-03-11 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSFIFIDELSELD